An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL Administered as Infusions Every 3 Weeks in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL Administered as Infusions Every 3 Weeks in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Aldoxorubicin (Primary) ; Doxorubicin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 13 Aug 2013 Planned End Date changed from 31 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 03 Jun 2013 Preliminary results were presented at the 2013 American Society of Clinical Oncology (ASCO) conference, according to a CytRx Corporation media release.
    • 20 May 2013 Planned number of patients changed from 18 to 24, based on information in a CytRx Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top